Indian Immunologicals Ltd to begin production of drug substance for Covaxin under Mission Covid Suraksha

The Centre decided to support Hyderabad-based Indian Immunological limited (IIL), with grants under the Mission COVID Suraksha, to develop the drug substance for Bharat Biotech’s Covid vaccine, Covaxin.

In a bid to augment the production of coronavirus vaccine doses, the central government has decided to support Hyderabad-based Indian Immunological limited (IIL), with grants under the Mission Covid Suraksha, to develop the drug substance for Bharat Biotech’s Covid vaccine, Covaxin. A technical collaboration agreement has been reached between IIL and Bharat Biotech. On this, Managing Director of Indian Immunological Limited, Dr K Anand Kumar, said that the IIL is planning to start the production of the drug substance for Covaxin from June 15 and send out the first batch to Bharat Biotech by July. Stating that Indian Immunological is expected to produce the drug substance for about 10-15 million doses per month, Dr Anand Kumar added that it will be initially 2-3 million doses and will later be scaled up to 6-7 million per month later in the year.